Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…
SANTA CLARA, CA / ACCESSWIRE / November 13, 2023 / Zeto, Inc., an innovative EEG brain monitoring company, is excited…
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with…
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE…
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,…
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,…
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in…
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity…
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) --…
Psychedelic Science 2023 was the breakthrough conference in psychedelics over 5 days in June 2023 in Denver, CO. Hosted by…